NCT00585117终止不适用
Pilot Study of (61)CuATSM-PET Imaging in Cancer Patients
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 9
- 试验地点
- 2
- 主要终点
- To validate the CuATSM-PET imaging by correlation to the serum level of osteopontin, a marker of hypoxia
研究概览
简要总结
Hypoxia is a key factor in malignant progression of a neoplasm. It is our aim to explore the basis for quantitative in vivo tumor imaging by Cu-61 diacetyl-bis(N4-methylthiosemicarbazone)PET imaging as a surrogate of tissue hypoxia. We hypothesize that the hypoxia levels are predictive of the tumor response to therapy. Patients will have 2 CU-ATSM PET scans done and the goal is to show spatially stable tracer distributions that correlate with tumor hypoxia. This study will serve as a pilot study for a PO1 submission
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able to tolerated a PET/CT scan
- •Age 18 or older
- •Patient being considered for XRT for treatment of their cancer
- •Able to provide written informed consent
排除标准
- •severe claustrophobia or inability to tolerate the PET scan
- •pregnant or breastfeeding women
- •Patients that need supplemental oxygen
- •Patients enrolled in experimental treatments
结局指标
主要结局
To validate the CuATSM-PET imaging by correlation to the serum level of osteopontin, a marker of hypoxia
时间窗: end of study
次要结局
- To assess the technical and logistic feasibility of CuATSM-PET scans in a population of cancer patients(end of study)
- To test reliability of the CuATSM uptake by quantifying the reproducibility of the pre-treatment CuATSM_PET scans(end of study)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell TherapyRecurrent Aggressive Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent High Grade B-Cell LymphomaRecurrent Malignant NeoplasmRecurrent Plasma Cell MyelomaRecurrent Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaRefractory Aggressive Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory High Grade B-Cell LymphomaRefractory Malignant NeoplasmRefractory Plasma Cell MyelomaRefractory Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaNCT04409314University of California, San Francisco23
Unknown
不适用
Hypoxia Imaging With 18F FAZA. Prognostic Impact in Cervical CancerUterine Cervical NeoplasmsNCT00388687Medical University of Vienna25
终止
2 期
Tumor Hypoxia With HX4 PET in Several DiseasesEsophageal NeoplasmsNeoplasm Metastases, BrainRectal NeoplasmsBrain Neoplasm, PrimaryProstatic NeoplasmsNCT02584400Maastricht Radiation Oncology1
已完成
早期 1 期
BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation TherapyHepatocellular CarcinomaNCT05250895Emory University9
已完成
不适用
Tumor hypoxia measured with F-MISO-PET in the course of irradiation of head and neck cancer: adoption of the method into clinical routine and evaluation of the dataC10C13Malignant neoplasm of oropharynxMalignant neoplasm of hypopharynxDRKS00006007niversitätsklinikum DresdenKlinik für Strahlentherapie und Radioonkologie59